Loading data for ANRO — first visit, this takes a few seconds.

Alto Neuroscience, Inc. (ANRO)

NYSE: ANRO · 即時價格 · USD

32.00

+0.32 (1.01%)

收盤價： Sep 11, 2026, 3:59 PM

32.00

-0.05%

盤後: 4:01 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

1.01% (1D)

買價	31.11
市值	1.26B
營收 (ttm)	n/a
淨利（ttm）	-84.2M
	1.16
	-2.32
	n/a
	-9.74
P/B (ttm)	5.12
P/S (ttm)	0.00
財報日期	Nov 11, 2026

賣價	32.03
成交量	415,741
20 日平均成交量	555,237
開盤價	32.00
前收盤價	31.68
當日區間	31.12 - 33.13
52 週範圍	3.59 - 37.48
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive d...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Feb 2, 2024

員工 68

證券交易所 NYSE

股票代號 ANRO

網站 https://www.altoneuroscience.com

完整的公司簡介

財務表現

Alto Neuroscience 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -63.24M，較前期增加 2.94%。

財務報表

財報驚奇

Alto Neuroscience 已於 Aug 12, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.65 超出預期 0.12, 年增 0.00% 成長.

下次財報發布

Alto Neuroscience, Inc. 的下次財報預計於 Nov 11, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

3 週前 · Simply Wall St.

Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?

Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0...

3 週前 · Simply Wall St.

Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?

Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with...

3 週前 · Simply Wall St.

Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans

Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last ...

2 月前 · Insider Monkey

Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list. On June 15, ALTO high...

3 月前 · Motley Fool

Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing

COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office m...

第 1 頁，共 2 頁

Alto Neuroscience, Inc. (ANRO)